Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Invega
Pharma
Teva, Viatris revive patent challenge on J&J schizophrenia drug
Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia drug.
Fraiser Kansteiner
Apr 2, 2024 11:12am
Arbitration win over J&J gives Alkermes a $425M boost
Jun 6, 2023 3:23pm
J&J successfully defends against Viatris' Invega copycat
May 18, 2023 10:41am
FDA approves Teva, MedinCell's long-acting schizophrenia therapy
May 1, 2023 9:30am
Which drug price increases led to the most US spending?
Dec 7, 2022 9:20am
FDA rejects Teva, MedinCell's schizophrenia drug
Apr 20, 2022 10:53am
